Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
Article
PubMed
Google Scholar
D’Amico AV. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen Era. J Clin Oncol. 2003;21:2163–72.
Article
PubMed
Google Scholar
Mottet N, Bellmunt JEB, Bergh R, Bolla M, Casteren N, Conford P. EAU Guidelines on Prostate Cancer. 2015. February.
Google Scholar
Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;24(February 2002):mdv222.
Google Scholar
Thompson I, Thrasher J, Gunnar Aus M, Burnett A, Canby-Hagino E, Cookson M, D’Amico A, Dmochowski R, Eton D, Forman J, Goldenberg S, Hernandez J, Higano C, Kraus S, Moul J, Tangen C. Guideline for the management of clinically localized prostate cancer: 2007 update. 2009.
Google Scholar
Sanda MG, Dunn RL, Michalaski J, et al. Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med. 2008;358:1250–61.
Article
CAS
PubMed
Google Scholar
Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436–45.
Article
CAS
PubMed
PubMed Central
Google Scholar
Marberger M, Carroll PR, Zelefsky MJ, Coleman JA, Hricak H, Scardino PT, Abenhaim LL. New treatments for localized prostate cancer. Urology. 2008;72(6 Suppl):S36–43.
Article
PubMed
Google Scholar
Polascik TJ, Mouraviev V. Focal therapy for prostate cancer. Curr Opin Urol. 2008;18:269–74.
Article
PubMed
Google Scholar
Valerio M, Ahmed HU, Emberton M, Lawrentschuk N, Lazzeri M, Montironi R, Nguyen PL, Trachtenberg J, Polascik TJ. The role of focal therapy in the management of localised prostate cancer: a systematic review. Eur Urol. 2013;66:732–51.
Article
PubMed
Google Scholar
Lee EW, Wong D, Prikhodko SV, Perez A, Tran C, Loh CT, Kee ST. Electron microscopic demonstration and evaluation of irreversible electroporation-induced nanopores on hepatocyte membranes. J Vasc Interv Radiol. 2012;23:107–13.
Article
PubMed
Google Scholar
Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat. 2007;6:313–20.
Article
PubMed
Google Scholar
Davalos RV, Mir LM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33:223–31.
Article
CAS
PubMed
Google Scholar
van den Bos W, de Bruin DM, Jurhill RR, Savci-Heijink CD, Muller BG, Varkarakis IM, et al. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients. World J Urol. 2015.
Scheffer HJ, Nielsen K, De Jong MC, Van JM TAA, Vieveen JM, Bouwman A, Meijer S, Van Kuijk C, Van Den Tol P, Meijerink MR. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25:997–1011.
Article
PubMed
Google Scholar
Tsivian M, Polascik TJ. Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int. 2013;112:526–30.
Article
PubMed
Google Scholar
Li W, Fan Q, Ji Z, Qiu X, Li Z. The effects of irreversible electroporation (IRE) on nerves. PLoS One. 2011;6:e18831.
Article
CAS
PubMed
PubMed Central
Google Scholar
Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;6:295–300.
Article
PubMed
Google Scholar
Neal RE, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A, Smith R, Davalos RV, Thomson KR. In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate. 2014;74:458–68.
Article
PubMed
Google Scholar
Rubinsky B. Irreversible Electroporation. 2010. ISBN: 978-3-642-05419-8.
Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:343–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ting F, Tran M, Böhm M, Siriwardana A, Van Leeuwen PJ, Haynes A-M, Delprado W, Shnier R, Stricker PD. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer Prostatic Dis 2015(August):1–7.
van den Bos W, de Bruin DM, van Randen A, Engelbrecht MRW, Postema AW, Muller BG, et al. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy. Eur Radiol. 2015.
Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361:1704–6.
Article
CAS
PubMed
Google Scholar
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Prostate Cancer Index Composite (Epic) for comprehensive assessment of health-related. Urology. 2000;56:899–905.
Article
CAS
PubMed
Google Scholar
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.
Article
CAS
PubMed
Google Scholar
Barry MJ. Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia. Urology. 2001;58(6 Suppl 1):25–32.
Article
CAS
PubMed
Google Scholar
de la Rosette J, Ahmed H, Barentsz J, Johansen TB, Brausi M, Emberton M, Frauscher F, Greene D, Harisinghani M, Haustermans K, Heidenreich A, Kovacs G, Mason M, Montironi R, Mouraviev V, de Reijke T, Taneja S, Thuroff S, Tombal B, Trachtenberg J, Wijkstra H, Polascik T. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24:775–80.
Article
PubMed
Google Scholar
Hu Y, Ahmed HU, Carter T, Arumainayagam N, Lecornet E, Barzell W, Freeman A, Nevoux P, Hawkes DJ, Villers A, Emberton M, Barratt DC. A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy. BJU Int. 2012;110:812–20.
Article
PubMed
Google Scholar
Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG. Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate. 2013;73:778–87.
Article
PubMed
Google Scholar
Kuru TH, Roethke MC, Rieker P, Roth W, Fenchel M, Hohenfellner M, Schlemmer HP, Hadaschik BA. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112:1080–7.
Article
CAS
PubMed
Google Scholar
Smeenge M, Mischi M, Laguna Pes MP, de la Rosette JJMCH, Wijkstra H. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol. 2011;29:581–7.
Article
PubMed
PubMed Central
Google Scholar
Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012;13:622–32.
Article
PubMed
PubMed Central
Google Scholar
Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C, Emberton M. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer. 2009;101:19–26.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, Van Der Meulen J, Emberton M. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol. 2011;185:1246–54.
Article
CAS
PubMed
Google Scholar
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–74.
Article
CAS
PubMed
Google Scholar
Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, Moul JW, Pinto PA, Rastinehad AR, Robertson C, de la Rosette J, Sanchez-Salas R, Jones JS, Ukimura O, Verma S, Wijkstra H, Marberger M. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113:218–27.
Article
PubMed
Google Scholar
Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol. 2006;176:2432–7.
Article
PubMed
Google Scholar
Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker PD. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. BJU Int. 2016;117:48–54.
Article
PubMed
Google Scholar
van Gemert MJC, Wagstaff PGK, de Bruin DM, van Leeuwen TG, van der Wal AC, Heger M, van der Geld CWM. Irreversible electroporation: just another form of thermal therapy? Prostate. 2015;75:332–5.
Article
PubMed
Google Scholar